ChiCTR‐INR‐17012212.

Study name	Use of sirolimus in patients with primary idiopathic membranous nephropathy: a prospective randomised control trial
Methods	Study design: RCT Study duration: planned 28 July 2017 to 31 May 2019 Sample size: 70 planned
Participants	Setting: single centre Country: China Inclusion criteria: 18 to 70 years; diagnosed as primary membranous nephropathy by renal biopsy and exclusion of secondary causes; corticosteroids and immunosuppressive agents not in the recent 3 months; BP < 140/90 mm Hg; proteinuria ≥ 3.5 g/day and eGFR ≥ 45mL/min/1.73 m²; with at least 3‐month treatment of maximum tolerance dosage of ACEi/ARB; SCr ≤ 133 µmol/L; agree to sign informed consent Exclusion criteria: any type of secondary membranous nephropathy by renal biopsy; any other type of kidney disease; uncontrolled infection; Interstitial pneumonia; new onset of cardiovascular disease in recent 3 months; severe liver disease, liver enzyme elevation is not higher than 3 times; uncontrolled severe hypertension; A new or recurring malignancy within 8.5 years; peptic ulcer or active digestive tract bleeding; severe autoimmune disease; pregnancy, lactation or scheduled pregnancy; expected survival was less than December; other clinical studies are currently in progress; do not agree to sign informed consent; the researchers found other conditions unsuitable for the study
Interventions	Group 1 CSA Group 2 CSA + sirolimus
Outcomes	Proteinuria
Starting date	28 July 2017
Contact information	Fang Wang, wangfang@bjmu.edu.cn
Notes	Sponsor: Huabei Pharmaceutical Company Status: recruiting (refreshed 1 Aug 2017)